2021
Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms
2017
Thoracic aortic aneurysm: unlocking the “silent killer” secrets
Saeyeldin AA, Velasquez CA, Mahmood SUB, Brownstein AJ, Zafar MA, Ziganshin BA, Elefteriades JA. Thoracic aortic aneurysm: unlocking the “silent killer” secrets. General Thoracic And Cardiovascular Surgery 2017, 67: 1-11. PMID: 29204794, DOI: 10.1007/s11748-017-0874-x.Peer-Reviewed Original ResearchConceptsAortic aneurysmAngiotensin receptor blockersFamilial patternBicuspid aortic valveAbdominal aortic aneurysmRisk of ruptureDifferent embryologic originsReceptor blockersBeta blockersType of repairThoracic aneurysmInflammatory disordersFemale sexSerum biomarkersAortic valveWorse outcomesEmbryologic originMedical treatmentEnzyme inhibitorsAneurysmsSilent killerIntracranial aneurysmsNatural historyOnly reliable methodPattern of inheritance